Efficacy of vitamin D supplementation among persons living with HIV/AIDS in Sao Paulo city, Brazil

Carregando...
Imagem de Miniatura
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER BRAZIL
Citação
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, v.25, n.3, article ID 101598, 5p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Hypovitaminosis D is now considered a pandemic, especially among more vulnerable populations and in HIV-infected subjects, with 80% presenting levels below 30 ng/mL. As there is no consensus on the more adequate dosage needed to correct such deficiency, the objective of this study was to evaluate 25 (OH) vitamin D supplementation in HIV-1 patients deficient of vitamin D. A total of 73 HIV-1-infected patients were included, drawn from a cohort of 435 patients; 37 patients were randomized to the active group, supplemented once a week with 50,000 UI vitamin D by mouth (group 1) and 36 to the placebo group (group 2). The study period ranged from June 2016 to September 2017. Variables involved in vitamin D metabolism and risk factors associated with hypovitaminosis were evaluated. The mean age was 45 years and 31.5 % were women. Vitamin D supplementation was effective in normalizing serum levels after six months in group 1 (mean 35 ng/mL compared to 21 ng/mL for the placebo group; p = 0.04). No patient reached blood levels considered toxic (>100 UI). Efavirenz use can negatively influence vitamin D levels and supplementation is necessary as a likely adjunct to improving CD4+ T cells, resulting in greater effectiveness of the treatment. A weekly oral dose of 50,000 IU of vitamin D was sufficient to normalize the vitamin deficiency, safely and with good adherence among persons living with HIV/AIDS in Brazil. (C) 2021 Sociedade Brasileira de Infectologia.
Palavras-chave
Vitamin D deficiency, HIV, supplementation, Brazil
Referências
  1. Adams JS, 2010, J CLIN ENDOCR METAB, V95, P471, DOI 10.1210/jc.2009-1773
  2. Aibana O, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002907
  3. Silva BCC, 2008, ARQ BRAS ENDOCRINOL, V52, P482, DOI 10.1590/S0004-27302008000300008
  4. Holick MF, 2017, REV ENDOCR METAB DIS, V18, P153, DOI 10.1007/s11154-017-9424-1
  5. Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385
  6. Marques CDL, 2010, REV BRAS REUMATOL, V50, P73
  7. Lopes VM, 2017, ARCH ENDOCRIN METAB, V61, P21, DOI 10.1590/2359-3997000000216
  8. Luetkemeyer Anne F, 2012, Top Antivir Med, V20, P48
  9. Marantes I, 2011, J BONE MINER RES, V26, P2860, DOI 10.1002/jbmr.510
  10. Mithal A, 2009, OSTEOPOROSIS INT, V20, P1807, DOI 10.1007/s00198-009-0954-6
  11. Canuto JMP, 2015, ARCH ENDOCRIN METAB, V59, P34, DOI 10.1590/2359-3997000000007
  12. Pornpaisalsakul K, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25624
  13. Rizzoli R, 2008, BONE, V42, P246, DOI 10.1016/j.bone.2007.10.005
  14. Sales SM, 2014, SCI REP-UK, P1
  15. Stallings VA, 2015, PEDIATR INFECT DIS J, V34, pE32, DOI 10.1097/INF.0000000000000483